Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Sphingosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.64 |
| ▸ | TSPO | P30536 | 1/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | GMNN | O75496 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | CETP | P11597 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL27759087 | 0.99 | MEN1 (0.69) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosine SCHEMBL1161567 | 0.89 | S1PR1 (0.73) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Miltefosine SCHEMBL28144581 | 0.87 | MEN1 (0.81) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosine SCHEMBL28104811 | 0.86 | S1PR1 (0.70) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosine SCHEMBL5826051 | 0.85 | S1PR1 (0.74) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL195873 | 0.85 | MEN1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL196291 | 0.85 | MEN1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL196365 | 0.83 | MEN1 (0.78) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL12513601 | 0.83 | MEN1 (0.78) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosine SCHEMBL29008881 | 0.83 | SPHK2 (0.68) | MEN1KMT2AS1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114994-A1 | PROSTHETIC VALVE LEAFLET MATERIAL, VALVE LEAFLET, VALVE AND PREPARATION METHOD | VENUS MEDTECH HANGZHOU INC (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260041823-A1 | IMPLANTABLE MATERIAL AND SYNTHESIS METHOD THEREFOR AND PROSTHETIC HEART VALVE | VENUS MEDTECH HANGZHOU INC (CN) | 2026-02-12 | — | — | US | claimed |
| WO-2025000650-A1 | ARTIFICIAL VALVE LEAFLET MATERIAL, VALVE LEAFLET, VALVE AND PREPARATION METHOD | 杭州启明医疗器械股份有限公司 | 2025-01-02 | — | — | WO | claimed |
| WO-2024216794-A1 | IMPLANTABLE MATERIAL AND SYNTHESIS METHOD THEREFOR AND PROSTHETIC HEART VALVE | 杭州启明医疗器械股份有限公司 | 2024-10-24 | — | — | WO | claimed |
| WO-2022063201-A1 | COMPOUND AND METHOD FOR ENHANCING T-CELL FUNCTION | 中国科学院动物研究所 | 2022-03-31 | — | — | WO | claimed |
| CN-112915093-A | Application of sphingosylphosphorylcholine in inducing apoptosis of tumor cells | 山东大学 | 2021-06-08 | — | — | CN | claimed |
| US-20260114994-A1 | PROSTHETIC VALVE LEAFLET MATERIAL, VALVE LEAFLET, VALVE AND PREPARATION METHOD | VENUS MEDTECH HANGZHOU INC (CN) | 2026-04-30 | — | — | US | disclosed |
| CN-119861166-A | Two-dimensional LC-MS/MS system | 建新公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119300865-A | Lipid nanoparticle formulations for central nervous system delivery | 卡耐基梅隆大学 | 2025-01-10 | — | — | CN | disclosed |
| WO-2025000650-A1 | ARTIFICIAL VALVE LEAFLET MATERIAL, VALVE LEAFLET, VALVE AND PREPARATION METHOD | 杭州启明医疗器械股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-114364980-B | Two-dimensional LC-MS/MS system | 建新公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119112789-A | Brain-targeted stem cell membrane bionic cationic liposome and preparation method and application thereof | 浙江大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024216794-A1 | IMPLANTABLE MATERIAL AND SYNTHESIS METHOD THEREFOR AND PROSTHETIC HEART VALVE | 杭州启明医疗器械股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-1999046277-A1 | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0072286-B2 | ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS | FIDIA S.p.A. (IT) | 1992-12-09 | — | — | EP | disclosed |
| US-4897382-A | Nervous system disorders | FIDIA S.P.A. (IT) | 1990-01-30 | — | — | US | disclosed |
| US-4897381-A | STIMULATED BIOLOGICALLY ACTIVE CARBOXYLIC ACIDS BOUND TO PHOSPHATIDES; ANTICONVULSANTS; PROLACTIN INHIBITORS; ANTILEPTIC AGENTS | FIDIA S.P.A. (IT) | 1990-01-30 | — | — | US | disclosed |
| US-4757053-A | Peripheral nervous system disorders | FIDIA, S.P.A. (IT) | 1988-07-12 | — | — | US | disclosed |
| EP-0072286-B1 | ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS | FIDIA S.p.A. (IT) | 1986-10-29 | — | — | EP | disclosed |
| EP-0072286-A1 | Organic amide compounds derived from nitrogenous lipids | FIDIA S.p.A. (IT) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114994-A1 | PROSTHETIC VALVE LEAFLET MATERIAL, VALVE LEAFLET, VALVE AND PREPARATION METHOD | TNNT2, MB, TTN | MEN1 4751/4885KMT2A 4082/4885S1PR1 4642/4885 |
| US-20260041823-A1 | IMPLANTABLE MATERIAL AND SYNTHESIS METHOD THEREFOR AND PROSTHETIC HEART VALVE | CAD, ACSL1, DSP | MEN1 3790/4885KMT2A 4111/4885S1PR1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.